[go: up one dir, main page]

NO20045534L - Sammensetninger og fremgangsmater for lindring av human kvinnelig seksuell feilfunksjon - Google Patents

Sammensetninger og fremgangsmater for lindring av human kvinnelig seksuell feilfunksjon

Info

Publication number
NO20045534L
NO20045534L NO20045534A NO20045534A NO20045534L NO 20045534 L NO20045534 L NO 20045534L NO 20045534 A NO20045534 A NO 20045534A NO 20045534 A NO20045534 A NO 20045534A NO 20045534 L NO20045534 L NO 20045534L
Authority
NO
Norway
Prior art keywords
female sexual
sexual dysfunction
methods
compositions
relief
Prior art date
Application number
NO20045534A
Other languages
English (en)
Norwegian (no)
Inventor
James L Yeager
Nadir Bueyuektimkin
Mingqi Lu
Y Joseph Mo
Servet Bueyuektimkin
Original Assignee
Nexmed Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexmed Holdings Inc filed Critical Nexmed Holdings Inc
Publication of NO20045534L publication Critical patent/NO20045534L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20045534A 2002-07-02 2004-12-17 Sammensetninger og fremgangsmater for lindring av human kvinnelig seksuell feilfunksjon NO20045534L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/188,554 US6825234B2 (en) 1998-12-10 2002-07-02 Compositions and methods for amelioration of human female sexual dysfunction
PCT/US2003/020779 WO2004004689A1 (fr) 2002-07-02 2003-07-02 Compositions et methodes de correction de dysfonctionnements sexuels chez la femme

Publications (1)

Publication Number Publication Date
NO20045534L true NO20045534L (no) 2005-03-01

Family

ID=30114011

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045534A NO20045534L (no) 2002-07-02 2004-12-17 Sammensetninger og fremgangsmater for lindring av human kvinnelig seksuell feilfunksjon

Country Status (10)

Country Link
US (1) US6825234B2 (fr)
EP (1) EP1517672A1 (fr)
JP (1) JP2005535658A (fr)
CN (1) CN1665485A (fr)
AU (1) AU2003248785A1 (fr)
CA (1) CA2489563A1 (fr)
NO (1) NO20045534L (fr)
NZ (1) NZ537276A (fr)
WO (1) WO2004004689A1 (fr)
ZA (1) ZA200410009B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050004226A1 (en) * 1998-12-10 2005-01-06 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
KR20050119136A (ko) * 2003-03-21 2005-12-20 넥스메드 홀딩스 인코포레이티드 프로스타글란딘 조성물에 의한 혈관형성 촉진 및 방법
EP1608378A1 (fr) * 2003-04-02 2005-12-28 Nexmed (Holdings), Inc. Compositions de prostaglandine et leur utilisation dans le traitement du spasme vasculaire
US20050239742A1 (en) * 2004-04-08 2005-10-27 Vivus, Inc. Carrageenan-based formulations and associated methods of use
KR100558012B1 (ko) * 2004-07-16 2006-03-06 삼성전자주식회사 반도체 메모리 소자
GB0417401D0 (en) * 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
US20060040904A1 (en) * 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
US7619008B2 (en) * 2004-11-12 2009-11-17 Kimberly-Clark Worldwide, Inc. Xylitol for treatment of vaginal infections
US20060217443A1 (en) * 2005-03-28 2006-09-28 Kimberly-Clark Worldwide, Inc. Method for preventing and/or treating vaginal and vulval infections
US7786176B2 (en) * 2005-07-29 2010-08-31 Kimberly-Clark Worldwide, Inc. Vaginal treatment composition containing xylitol
WO2007076144A2 (fr) * 2005-12-27 2007-07-05 Duramed Pharmaceuticals, Inc. Compositions d'œstrogènes conjugués, applicateurs, kits et procédés pour les préparer et les utiliser
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
US7560489B2 (en) * 2006-10-11 2009-07-14 Nexmed Holdings, Inc. Stabilized prostaglandin E composition
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
BR112013025744A2 (pt) 2011-04-07 2016-08-16 Nexmed Holdings Inc composicões para tratamento da doença de raynaud
WO2014100599A1 (fr) 2012-12-21 2014-06-26 Teikoku Pharma Usa, Inc. Compositions et méthodes d'administration transdermique d'hormones et d'autres substances médicales
US20220401381A1 (en) * 2019-11-08 2022-12-22 Vella Bioscience, Inc. Peripherally acting cannabidiol (cbd)-containing compounds and uses thereof for enhancing female sexual function or treating female sexual disorders

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3069322A (en) 1958-05-28 1962-12-18 Bergstrom Sune Pge and pgf
US3545439A (en) 1968-01-04 1970-12-08 Upjohn Co Medicated devices and methods
US3639561A (en) 1970-04-29 1972-02-01 Smith Kline French Lab Vaginal suppositories and impregnated tampons
US3852465A (en) 1972-09-21 1974-12-03 Upjohn Co Abortion by myometrial administration of prostaglandins
US4005221A (en) 1974-04-01 1977-01-25 Karim Sultanali M M Use of prostaglandins to induce menstruation
US4217360A (en) 1975-02-27 1980-08-12 Schering Aktiengesellschaft Novel 1,3-benzodioxaneprostanoic acid derivatives and process for the preparation thereof
US4043339A (en) 1976-02-02 1977-08-23 The Upjohn Company Method of and vaginal insert for prostaglandin administration
JPS52156913A (en) 1976-06-21 1977-12-27 Toko Yakuhin Kogyo Kk Production of injectionable medicine
AU519132B2 (en) 1978-01-31 1981-11-12 Kureha Kagaku Kogyo K.K. Prostaglandin-steroid conjugates
US4254145A (en) 1978-08-16 1981-03-03 American Cyanamid Company Topical application of prostaglandin hypotensive agents
JPS5573676A (en) 1978-11-30 1980-06-03 Ono Pharmaceut Co Ltd Simulated compound of prostaglandin i2 and its preparation
JPS5589297A (en) 1978-12-28 1980-07-05 Kureha Chem Ind Co Ltd Prostaglandin derivative, its preparation and its drug
SE431821B (sv) 1979-01-29 1984-03-05 Perstorp Ab Lagringsstabilt, prostaglandininnehallande medicinskt preparat
US4311707A (en) 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
USRE30439E (en) 1979-03-12 1980-11-25 The Upjohn Company Treatment of genital tract diseases of domestic animals with prostaglandins
US4317447A (en) 1979-07-19 1982-03-02 Ortho Pharmaceutical Corporation Drug delivery system
US4318908A (en) 1979-12-06 1982-03-09 Kureha Kagaku Kogyo Kabushiki Kaisha Methylated prostaglandin derivatives
US4289785A (en) 1980-08-06 1981-09-15 The Upjohn Company Method and compositions involving prostaglandins
ZA831186B (en) 1982-03-22 1983-11-30 Upjohn Ltd Gelled pge2/triacetin solutions
US4557934A (en) 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US4515810A (en) 1983-10-06 1985-05-07 American Cyanamid Company Composition of matter
US4820732A (en) 1985-10-04 1989-04-11 The Upjohn Company Method and compositions for reducing dysfunction in angioplasty procedures
US4955878A (en) 1986-04-04 1990-09-11 Biotechnology, Inc. Kit for preventing or treating arterial dysfunction resulting from angioplasty procedures
US4889845A (en) 1986-06-09 1989-12-26 American Cyanamid Company Vehicle for topical application of pharmaceuticals
US4771004A (en) 1986-08-29 1988-09-13 Iprx, Inc. Method for in vitro determination of transdermal absorption
EP0266968A3 (fr) 1986-11-03 1988-08-24 Gérard G. Cohen Onguent gélifié contenant un agent vasodilatateur
US4861764A (en) 1986-11-17 1989-08-29 Macro Chem. Corp. Percutaneous absorption enhancers, compositions containing same and method of use
JPS63135333A (ja) 1986-11-26 1988-06-07 Nitto Electric Ind Co Ltd プロスタグランジン類含有貼付剤
US5219885A (en) 1987-02-16 1993-06-15 Froelich Juergen Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration
US4801587A (en) 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5082866A (en) 1988-06-01 1992-01-21 Odontex, Inc. Biodegradable absorption enhancers
US4980378A (en) 1988-06-01 1990-12-25 Odontex, Inc. Biodegradable absorption enhancers
IT1221826B (it) 1988-06-08 1990-07-12 Medico Harvey Srl Centro Preparato per uso topico per il trattamento terapeutico dell impotentia coeundi
SE463851B (sv) 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
JP2910857B2 (ja) 1989-04-04 1999-06-23 ニチバン株式会社 プロスタグランジンｅ１経皮吸収製剤
US5208031A (en) * 1989-06-06 1993-05-04 Kelly Patrick D Sexual lubricants containing zinc as an anti-viral agent
US5059603A (en) 1989-06-12 1991-10-22 Centuries Laboratories, Inc. Method and composition for treating impotence
JP3477197B2 (ja) 1990-04-25 2003-12-10 ヴィヴァス・インコーポレーテッド 勃起機能障害
US5242391A (en) 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
CA2046069C (fr) 1990-07-10 2002-04-09 Ryuji Ueno Traitement des maladies inflammatoires au moyen de composes de 15-cetoprostaglandine
US5962528A (en) 1991-07-03 1999-10-05 Scott; Nathan Earl Prostaglandin E2 /F2α combination for treating impotence
US5981593A (en) 1991-07-03 1999-11-09 Scott; Nathan Earl Prostaglandin E2 treatment of impotence
AU2300092A (en) 1991-07-03 1993-02-11 Nathan E. Scott Prostaglandin e2 treatment of impotence
WO1999030718A2 (fr) 1997-12-18 1999-06-24 Nathan Earl Scott COMBINAISON DE PROSTAGLANDINES E2/F2α, DESTINEE AU TRAITEMENT DE L'IMPUISSANCE ET A L'ACCROISSEMENT DE L'EXCITATION SEXUELLE
US6291528B1 (en) 1991-07-03 2001-09-18 Nathan Earl Scott Prostaglandin E1/F2 in combination with prostaglandin F2α for enhancing female sexual arousal
JP2671248B2 (ja) 1991-10-23 1997-10-29 ブロック・ドラッグ・カンパニー・インコーポレイテッド 薬効または化粧効果成分の浸透性増進方法
CA2123007A1 (fr) 1991-11-08 1993-05-13 Ken-Ichi Nishimura Preparation pharmaceutique contenant un compose de la prostaglandine, pour administration rectale ou vaginale
US5773457A (en) 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions
BR9203277A (pt) 1992-08-21 1994-03-01 Cesar Roberto Dias Nahoum Utilizaccao de drogas eretogenicas e respectivas metodologias de aplicacao
US5324746A (en) 1993-02-12 1994-06-28 Mckee Rex N Method of treating damaged mucosal and epithelial tissues with misoprostol
US5698589A (en) 1993-06-01 1997-12-16 International Medical Innovations, Inc. Water-based topical cream containing nitroglycerin and method of preparation and use thereof
US5565466A (en) 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
ATE187071T1 (de) 1993-10-27 1999-12-15 Upjohn Co Stabilisiertes prostaglandin e1
US5380760A (en) 1993-11-19 1995-01-10 Minnesota Mining And Manufacturing Company Transdermal prostaglandin composition
AU5358896A (en) 1995-03-14 1996-10-02 Vivus, Inc. Method and kit for preventing erectile dysfunction
US5661178A (en) 1995-09-01 1997-08-26 Allergan Method for effecting vasodilation with (1,5-inter)aryl prostaglandin derivatives
US6251436B1 (en) 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US6036977A (en) 1995-09-29 2000-03-14 L.A.M. Pharmaceutical Corp. Drug preparations for treating sexual dysfunction
ATE229817T1 (de) * 1996-10-24 2003-01-15 Alza Corp Penetrationsfördernde substanzen für die transdermale verabreichung von wirkstoffen, vorrichtungen und verfahren zur herstellung
GR1002847B (el) 1997-05-06 1998-01-27 Χρηση της μισοπροστολης ή/και της μισοπροστολης οξυ για την παρασκευη φαρμακευτικου προιοντος για τη θεραπευτικη αντιμετωπιση των δυσλειτουργιων της στυσεως
US20020004529A1 (en) 1997-10-20 2002-01-10 Gary W. Neal Methods, compositions, and kits for enhancing female sexual desire and responsiveness
US5877216A (en) 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
WO1999021562A1 (fr) 1997-10-28 1999-05-06 Asivi, Llc Traitement du dysfonctionnement sexuel chez la femme
AUPP010397A0 (en) 1997-10-30 1997-11-20 Vaisman, Jakov Method and composition for treatment of sexual dysfunction
US6414028B1 (en) 1997-11-05 2002-07-02 Nexmed Holdings, Inc. Topical compositions containing prostaglandin E1
US6046244A (en) 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
US6046240A (en) 1998-05-01 2000-04-04 Harvard Scientific Corporation Methods for treating female sexual dysfunction
US5891915A (en) 1998-05-01 1999-04-06 Wysor; Michael S. Method for enhancing female sexual response and an ointment therefor
US6031002A (en) 1998-05-01 2000-02-29 Michael Ebert Method for enhancing female sexual response and a composition therefor
US6486207B2 (en) 1998-12-10 2002-11-26 Nexmed (Holdings), Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6323241B1 (en) 2000-01-10 2001-11-27 Nexmed (Holdings) Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US6693135B2 (en) 2000-01-10 2004-02-17 Nexmed (Holdings) Incorporated Prostaglandin compositions and methods of treatment for male erectile dysfunction
US6403658B1 (en) 2000-09-21 2002-06-11 Shaina Toppo Genital vasodilator

Also Published As

Publication number Publication date
WO2004004689A1 (fr) 2004-01-15
EP1517672A1 (fr) 2005-03-30
CA2489563A1 (fr) 2004-01-15
US20030129241A1 (en) 2003-07-10
JP2005535658A (ja) 2005-11-24
NZ537276A (en) 2007-06-29
US6825234B2 (en) 2004-11-30
CN1665485A (zh) 2005-09-07
WO2004004689A8 (fr) 2004-04-15
AU2003248785A1 (en) 2004-01-23
ZA200410009B (en) 2006-06-28

Similar Documents

Publication Publication Date Title
NO20045534L (no) Sammensetninger og fremgangsmater for lindring av human kvinnelig seksuell feilfunksjon
PT1137409E (pt) Composicoes e metodos para melhoramento da disfuncao sexual feminina humana
TW200505508A (en) Methods of administering a dermatological agent to a subject
WO2004089357A3 (fr) Preparation antifongique a base de triterpene et d'huile essentielle
MX2010005210A (es) Formulacion de aceite de oliva para alivio del dolor.
EP2351561A3 (fr) Nouvelles méthodes et compositions pour alléger la douleur
MXPA06002726A (es) Metodo para identificar agonistas mejorados no sedantes de alfa-2.
BRPI0411826A (pt) métodos de prevenir e reduzir a gravidade de estados associados ao estresse
GEP20063982B (en) Use of prostaglandin compositions with male persons for treatment of erectile dysfunction
EP2513343A4 (fr) Procédés et compositions pour traiter l'inflammation de la peau
WO2004037173A3 (fr) Procede de traitement de la dyserection et d'augmentation de la libido chez l'homme
WO2004089415A3 (fr) Therapie combinatoire utilisant un inhibiteur de 11$g(b)-hydroxysteroide deshydrogenase de type 1 et agoniste du recepteur de glucocorticoides pour minimiser les effets secondaires associes a la therapie a base d'agoniste du recepteur de glucocorticoides
NO20071742L (no) Kinazoliner som er nyttige som modulatorer av ionekanaler
CA2420895A1 (fr) Methode pour traiter la dyserection et augmenter la libido chez l'homme
BR0311939A (pt) composição farmacêutica, método para tratar inflamação em um mamìfero e uso de uma citocina protetora de tecido orgánico
WO2004093814A3 (fr) Compositions a base d'un inhibiteur selectif de la cyclooxygenase-2 et d'un bloqueur du canal d'ions sodium pour le traitement de la douleur, de l'inflammation ou de troubles medies par l'inflammation
AU2002302587A1 (en) Acne treatment with lipooxigenase inhibitors
WO2009015014A3 (fr) Procédé multiphasique de traitement de la douleur et/ou de l'inflammation
AR047796A1 (es) Composiciones cosmeticas que exhiben propiedades humectantes duraderas
ECSP045153A (es) Metodo y composición para aumentar la potencia de un analgésico de narcotico.
WO2003032985A3 (fr) Nouvelles methodes de traitement d'infections bacteriennes et fongiques locales
IN2014DE01913A (fr)
WO2005023189A3 (fr) Procede de prevention ou de traitement de la douleur, de l'inflammation, et de troubles lies a l'inflammation avec un inhibiteur selectif de cox-2 en combinaison avec un agent donneur de monoxyde d'azote et compositions en contenant
CA2441461A1 (fr) Formulations en application locale pour l'administration transdermique de niacine, et procedes pour traiter l'hyperlipemie
WO2003082193A3 (fr) La suramine et ses derives, utilises comme microbicide et contraceptif

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application